asa statement on glp 1 Perioperative management of patients taking glucagon-like peptide receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus A very important and practice-changing

GLP-1 therapies commonly cause nausea, vomiting, and delayed gastric emptying

It does have a good track record in terms of safety, and it does not lead to weight gain or hypoglycemia

No insurance, membership fees, or hidden charges applyyou pay one flat monthly rate regardless of dose adjustments

Currently, there are 3 GLP-1 agonists that are FDA-approved for the treatment of obesity: Saxenda (Liraglutide)- a once-daily subcutaneous injection given in the back of the arm, the thigh, or the abdomen

No, Botox and dermal fillers are safe to receive while taking GLP-1 medications

Step 3 Approval, Payment, and Program Enrollment If the provider determines a prescription is appropriate, the patient receives an approval notification and completes payment for their program